Repaglinide FDA approval date

The FDA approved Repaglinide on 22 Dec 1997.

FDA approval date
22 Dec 1997

Drug identity checked against registry records

Included trials

TrialSponsorPhaseStatusPrimary completion
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsNCT07020221VSTMPhase 1, Phase 2Recruiting2028-12Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
1997-12-22DayRepaglinideFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA020741", "applicant_as_listed_by_fda": "GEMINI LABS LLC", "brand_names": ["PRANDIN"], "active_ingredients": ["REPAGLINIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19971222", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 19 Oct 2026 · Evidence last checked: 19 Oct 2026